Apimeds Pharmaceuticals US, Inc. (APUS)
4.60
-0.02
(-0.43%)
USD |
NYAM |
Oct 14, 10:12
Apimeds Pharmaceuticals US Debt to Equity Ratio : 0.1369 for June 30, 2026
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.1369 |
| March 31, 2026 | 0.0754 |
| December 31, 2025 | 0.0506 |
| September 30, 2025 | 0.0613 |
| June 30, 2025 | 0.0513 |
| March 31, 2025 | -0.4962 |
| Date | Value |
|---|---|
| December 31, 2024 | -0.4394 |
| September 30, 2024 | -0.5491 |
| June 30, 2024 | -0.5606 |
| March 31, 2024 | -1.084 |
| December 31, 2023 | 8.367 |
| September 30, 2023 | 4.907 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| ACADIA Pharmaceuticals, Inc. | 0.0565 |
| Alnylam Pharmaceuticals, Inc. | 2.206 |
| Anika Therapeutics, Inc. | 0.1839 |
| Savara, Inc. | 0.2117 |
| Vericel Corp. | 0.2556 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 127.62M |
| Total Liabilities (Quarterly) | 21.18M |
| Shareholders Equity (Quarterly) | 106.45M |
| Current Ratio | 0.5067 |
| Net Debt Paydown Yield | -20.17% |